Aprea Therapeutics Q3 net loss widens to $4.8 million; cash totals $37.8 million
Aprea Therapeutics reported a third-quarter 2026 net loss of $4.8 million, or $(0.09) per share, up from $3.0 million, or $(0.47) per share, a year earlier, as research and development spending rose. The company had $37.8 million in cash and cash equivalents at September 30, 2026, and expects that cash to fund operations into the first quarter of 2028, while it expands its Phase 1 trial of APR-1051.
Key points
- Q3 2026 operating loss was $5.2 million, compared with $3.1 million in Q3 2025; no grant revenue was recorded versus $1,848 a year earlier.
- R&D expenses were $3.3 million, up from $1.6 million, mainly due to a $2.1 million increase for the ACESOT-1051 trial.
- Cash and cash equivalents were $37.8 million at September 30, 2026, up from $14.6 million at December 31, 2025.
- Interim ACESOT-1051 data will be presented as an oral presentation on November 20, 2026, at the ENA 2026 symposium in Barcelona.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.